Form 4: Oruka Therapeutics Executive Sells Shares
Insider Transaction (Form 4)
Paul T Quinlan, General Counsel of Oruka Therapeutics, Inc., sold 52,000 shares of common stock on August 14, 2026.
Summary
- Option exercise/conversion: acquired 10,000 Common Stock at $7.80 ($78,000) on August 14, 2026; holds 41,034 after (Direct).
- Option exercise/conversion: acquired 42,000 Common Stock at $12.50 ($525,000) on August 14, 2026; holds 83,034 after (Direct).
- Open-market sale: disposed of 3,630 Common Stock at $106.05 ($384,963) on August 14, 2026; holds 79,404 after (Direct).
- Open-market sale: disposed of 10,434 Common Stock at $107.14 ($1,117,901) on August 14, 2026; holds 68,970 after (Direct).
- Open-market sale: disposed of 14,696 Common Stock at $107.97 ($1,586,779) on August 14, 2026; holds 54,274 after (Direct).
- Open-market sale: disposed of 10,200 Common Stock at $109.11 ($1,112,954) on August 14, 2026; holds 44,074 after (Direct).
- Open-market sale: disposed of 9,193 Common Stock at $110.00 ($1,011,266) on August 14, 2026; holds 34,881 after (Direct).
- Open-market sale: disposed of 3,847 Common Stock at $111.14 ($427,547) on August 14, 2026; holds 31,034 after (Direct).
- Option exercise/conversion: disposed of 10,000 Employee Warrant (right to buy) on August 14, 2026; holds 89,996 after (Direct).
- Option exercise/conversion: disposed of 42,000 Employee Stock Option (right to buy) on August 14, 2026; holds 120,500 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $5,641,409 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Paul T Quinlan — Officer (General Counsel)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-14 | Option exercise/conversion | Common Stock | 10,000 | $8 | $78.0K | 41,034 |
| 2026-08-14 | Option exercise/conversion | Common Stock | 42,000 | $13 | $525.0K | 83,034 |
| 2026-08-14 | Open-market sale | Common Stock | 3,630 | $106 | $385.0K | 79,404 |
| 2026-08-14 | Open-market sale | Common Stock | 10,434 | $107 | $1.1M | 68,970 |
| 2026-08-14 | Open-market sale | Common Stock | 14,696 | $108 | $1.6M | 54,274 |
| 2026-08-14 | Open-market sale | Common Stock | 10,200 | $109 | $1.1M | 44,074 |
| 2026-08-14 | Open-market sale | Common Stock | 9,193 | $110 | $1.0M | 34,881 |
| 2026-08-14 | Open-market sale | Common Stock | 3,847 | $111 | $427.5K | 31,034 |
| 2026-08-14 | Option exercise/conversion | Employee Warrant (right to buy) | 10,000 | — | — | 89,996 |
| 2026-08-14 | Option exercise/conversion | Employee Stock Option (right to buy) | 42,000 | — | — | 120,500 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-14 | Option exercise/conversion (10,000 shares) |
| 2026-08-14 | Option exercise/conversion (42,000 shares) |
| 2026-08-14 | Open-market sale (3,630 shares) |
| 2026-08-14 | Open-market sale (10,434 shares) |
| 2026-08-14 | Open-market sale (14,696 shares) |
| 2026-08-14 | Open-market sale (10,200 shares) |
| 2026-08-14 | Open-market sale (9,193 shares) |
| 2026-08-14 | Open-market sale (3,847 shares) |
| 2026-08-14 | Option exercise/conversion (10,000 shares) |
| 2026-08-14 | Option exercise/conversion (42,000 shares) |
Keywords
insider transaction, Form 4, ORKA, Oruka Therapeutics, Inc., bearish, Paul T Quinlan
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.